Skip to content
Ibumix
  • Technology
    • Bioavailability
    • The tablet problem
    • Lipid & liquid-crystal delivery
    • GRAS & established materials
    • TECHNOLOGY – The Ibumix™ Platform
    • Science and data
    • The Structural Problem Behind Poor Drug Solubility
    • Products
    • Drug-delivery and formulation glossary
  • Company
    • About Ibumix
    • Investor overview
    • Newsroom
    • Connect
  • Insights
Ibumix
  • Technology
    • Bioavailability
    • The tablet problem
    • Lipid & liquid-crystal delivery
    • GRAS & established materials
    • TECHNOLOGY – The Ibumix™ Platform
    • Science and data
    • The Structural Problem Behind Poor Drug Solubility
    • Products
    • Drug-delivery and formulation glossary
  • Company
    • About Ibumix
    • Investor overview
    • Newsroom
    • Connect
  • Insights

Tag: orforglipron

Two Roads to One Pill: Novo Nordisk's oral semaglutide tolerates the bioavailability ceiling with SNAC, while Eli Lilly's Foundayo (orforglipron) avoids it as a small molecule
12 August 202617 August 2026TechnologyBy George Forrest

Two Roads to One Pill

Ozempic is a pill now, but oral bioavailability wasn’t solved. How Novo Nordisk and Eli Lilly reached comparable results by two opposite routes.

Read more
© 2026 Ibumix.